Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer

Trial Profile

Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Cetuximab (Primary) ; Zirconium-89 cetuximab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms IMPACT-CRC
  • Most Recent Events

    • 01 Aug 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (n=44) assessing predictive biomarkers to identify patients with primary resistant mCRC using patient data from NCT02117466 and NCT01691391trials, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top